New ‘concerning’ data find that most US endoscopists aren’t following current polypectomy guidelines for polyps < 1 cm, ...
Amgen and AstraZeneca's Tezspire has claimed FDA approval as a treatment for chronic rhinosinusitis with nasal polyps (CRSwNP ...
The FDA approved tezepelumab-ekko (TEZSPIRE; AstraZeneca/Amgen) on Friday as an add-on maintenance treatment in patients aged ...
Hosted on MSN
My doctor found a colon polyp, now what?
Just saying the word colonoscopy makes some people feel uncomfortable. But consider this: Colorectal cancer is the second leading cause of cancer death in the world, yet it’s one of the most curable ...
The FDA approved Amgen's and AstraZeneca's drug to treat chronic rhinosinusitis with nasal polyps, an inflammatory condition of the sinuses and nasal passages. The companies said the approval was ...
The U.S. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic inflammatory sinus ...
Artificial intelligence (AI) in gastrointestinal (GI) endoscopy is shifting from algorithm development to real-world clinical use. Beyond polyp detection, ...
AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) has been approved in the US for the add-on maintenance treatment of ...
Amgen (NASDAQ:AMGN) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) approved TEZSPIRE® (tezepelumab-ekko) for the add-on maintenance treatment of inadequately ...
Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with ...
Amgen and AstraZeneca’s Tezspire (tezepelumab-ekko) gains FDA approval as an add-on maintenance therapy for patients aged 12 and older with inadequately controlled chronic rhinosinusitis with nasal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback